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Summary 
The mechanism of the structural alterations of the T cell receptor (TCR)-CD3 complex, which 
appear to be greatly responsible for immunosuppression in the tumor-beating status, was investigated 
in tumor-bearing mice. Splenic T cells from tumor-bearing hosts lost the expression of the CD3~" 
chain without being replaced by FcR% despite the normal expression of other components of 
the TCR complex. Tumor growth induced the accumulation of non-T, non-B cells in the spleen 
in correlation with the loss of ~'. Those cells were found to be macrophages that were able to 
induce the loss of ~', as well as structural changes of CD3"y/~e, even in freshly isolated normal 
T  cells by cell contact-dependent interaction. More importantly, macrophages activated with 
zymosan A  +  LPS but not residential macrophages were able to induce the similar abnormality 
of the TCR complex. These results indicate that macrophages in certain activation stages play 
a crucial role in causing an abnormal TCR complex in tumor-bearing conditions, as well as 
in regulating the structure of the TCR complex in immune responses. 
p rogression of tumor growth has been demonstrated to 
result in immunosuppression of T cell responses. The sup- 
pression has been attributed to the function of suppressor 
T cells, secretion of suppressive  cytokines from tumor cells, 
or the accumulation of suppressive  macrophages (1-3). Re- 
cently, structural abnormalities of the TCR-CD3 complex 
have been reported in splenic T cells from tumor-bearing mice 
(TBM) (4). These T ceils lost the expression of the ~" chain 
and reduced the CD33' chain as well as TCR-associated tyro- 
sine kinases,  p56 ~k and P59f~.  Although similar abnormali- 
ties of the TCR  complex have  been observed in  tumor- 
infiltrating and peripheral blood T cells from human cancer 
patients  (5-7),  the  mechanisms  of such  alterations  were 
unknown. 
The TCR-CD3 complex is responsible for specific antigen 
recognition, which activates T cells to exhibit effector func- 
tions including tumor rejection. The antigen recognition 
signals by clonotypic TCRo~/heterodimer are transduced 
into the cytoplasm through the CD3 complex, which is com- 
posed of six polypeptides: y~, 8~, and ~" dimers (8). The cy- 
toplasmic domain of the ~" chain has been demonstrated to 
be capable  of transducing  signals  independently of other 
TCR-CD3  components, and it has been thought to play a 
central role for signal transduction in T  cell activation (9). 
~" is also crucial for the cell surface expression of the TCR- 
CD3 complex (10). In ~'-deficient mice, the expression of the 
surface TCIL complex is greatly reduced, and proliferative 
responses of thymocytes and peripheral T cells are impaired 
(11). Therefore, suppression of immune responses in tumor- 
bearing hosts may be mostly attributable to the impairment 
of the TCR complex and its associated kinases. 
We have investigated the mechanism of the structural al- 
terations of the TCR complex in a tumor-bearing mouse 
model. Splenic T  cells from TBM lost the CD3~" chain in 
spite of normal expression of other components of the TCR 
complex. We demonstrated that macrophages accumulated 
in the TBM spleen, as well as activated macrophages in cer- 
tain stages, induced the loss of ~" even in freshly isolated normal 
T cells. Our results provide molecular approaches for under- 
standing the regulation of the expression of the TCR-CD3 
complex and immunosuppression in tumor-bearing condi- 
tions,  as well as in normal immune responses. 
Materials and Methods 
Animals.  To prepare TBM,  2  x  106 syngeneic colon carci- 
noma cells (colon 26) were implanted subcutaneously into 8-12- 
wk-old BALB/c mice (Japan SLC, Hamamatsu, Japan). 
Cell Preparation.  Lymphocytes from mesenteric lymph nodes 
and spleen, after depletion of erythrocytes,  were suspended  in RPMI 
1640 supplemented with 10% heat-inactivated FCS, 2 mM gluta- 
mine, 50/~M 2-ME, 10 mM Hepes, and 100 #g/ml kanamycin 
(complete medium). Splenic T cells were enriched through nylon- 
wool columns. Flow cytometric analysis with anti-CD3e  mAb 
showed that ",85% of the cells were T cells from normal mice 
and 30-40% from 6-9-wk TBM. The number ofT cells from TBM 
was adjusted to that of normal T cells according to flow cytometric 
analysis. Intestinal intraepithelial lymphocytes (i-IEL) were isolated 
as previously  described (12). Non-T, non-B cells were prepared from 
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(Jlj.10)  and elimination of B cells with anti-Ig-coated magnetic 
beads. Peritoneal  macrophages  were obtained from peritoneal  la- 
vage followed by elimination of B cells with anti-Ig-coated mag- 
netic beads. For activated macrophages,  mice were inoculated in- 
traperitoneally with 1 mg of zymosan A (Sigma Immunochemicals, 
St.  Louis,  MO),  followed  with 20/xg of LPS (0127:B8,  Sigma) 
1 wk later, and the peritoneal macrophages  were isolated 2 d later. 
Flow Cytometric  Analysis.  Cells from spleen, lymph nodes and 
i-IEL were stained with mAbs of appropriate  specificities and ana- 
lyzed on  a  FACScan  |  flow cytometer (Becton  Dickinson  Im- 
munocytometry  Systems, Mountain View, CA) using Lysis II soft- 
ware.  The following mAbs were used:  FITC-labeled  anti-CD3e 
(145-2Cll), PE-conjugated anti-CD45R/B220 (RA3-6B2),  anti- 
HSA (M1/69), anti-MHC classlI (anti-mouse I-A  q,b.d, I-E  k,d, 1E4) 
and FITC-conjugated anti-rat Ig (MAR18.5). Anti-Mac-1 (M1/70) 
and biotinylated anti-Gr-l(RB6-8C5) were generously provided by 
Dr.  K. Okumura (Juntendo University,  Tokyo, Japan). 
Cell Surface  Biotinylation, Immunoprecipitation,  and Two-dimensional 
SDS-PAGE Analysis.  Cells were surface labeled by biotinylation 
as previously described (13). Cells were then solubilized in a lysis 
buffer (1% digitonin, 50 mM Tris-HC1, pH 7.6,  150 rnM NaC1, 
10/zg/ml aprotinin, 10 #g/ml leupeptin, 1 mM PMSF, and 10 mM 
iodoacetamide).  The lysates were immunoprecipitated with anti- 
CD3e mAb (145-2Cll), anti-~"  mAb (H146.698A),  and anti-FcR  7 
antiserum,  which  were  kindly provided  by  Drs.  J.  Bluestone 
(University of Chicago, Chicago, IL), R.  Kubo (Cytel, Inc.,  La 
Jolla, CA), and C. Ra (Juntendo University),  respectively, analyzed 
on two-dimensional nonreducing-reducing SDS-PAGE (14%  for 
the first dimension and 16% for the second dimension) or single- 
dimensional SDS-PAGE (13%) under reducing condition, and trans- 
ferred onto a polyvinylidene fluoride membrane.  Biotinylated pro- 
teins on the membrane were detected using streptavidin-peroxidase 
(Vectastain Elite ABC kit; Vector Laboratories, Burlingame,  CA) 
and an ECL system (Amersham, Buckinghamshire, England). 
Results 
Selective Loss of the ~" Chain in the Splenic T  Cells of TBM. 
Splenic T  cells were isolated from normal mice and TBM 
that had been subcutaneously implanted with syngeneic colon 
carcinoma, colon 26, 2-9 wk before use. Tumor growth was 
specifically localized on  the back,  and no visceral invasion 
or metastasis was observed.  T  cells  were surface labeled by 
biotinylation, and the cell lysates were immunoprecipitated 
with  anti-CD3e  and  anti-~"  mAb  and  analyzed  by  two- 
dimensional SDS-PAGE (Fig. 1). CD3~'homodimers, clearly 
detected as an off-diagonal spot in  normal mice and 2-wk 
TBM,  were diminished in 4-wk TBM and completely lost 
in 6-wk TBM (Fig.  1 A).  The disappearance of ~" in whole 
lysates was confirmed by Western blotting with anti-~" mAb 
(data not shown).  In spite of the disappearance of ~', other 
components of the TCR-CD3 complex had not disappeared, 
even in the 6-wk TBM,  and the expression level of the cell 
surface TCR  complex was  not  altered (Fig.  1).  Although 
Mizoguchi et al.  reported  that  ~" was replaced by FcR  7  in 
their TBM  system (4),  FcR3' was not detected within the 
TCR complex of TBM by immunoprecipitation with anti- 
CD36 mAb  (Fig.  1), or even with anti-Fcg  7  Ab (data not 
Figure  I.  Time course of the disappearance 
of the CD3~"  chain associated with the TCR- 
CD3 complex and flow cytometric analysis of 
spleen cells in 2-6-wk TBM. (-4) The lysates  of 
surface-biotinylated  splenic T  cells (4  x  107) 
were immunoprecipitated  with anti-CD3e and 
-~" mAbs and analyzed on  14%  nonreducing 
(NR)-16  % reducing  (R) two-dimensional  SDS- 
PAGE. The positions of CD37~Se and ~"  chains, 
as well  as molecular  size  markers (in kilodahons), 
are indicated.  (B) Whole spleen cells  were stained 
with FITC-labeled  anti-CD3e and PE-conjugated 
anti-CD45R/B220 mAbs, and they were ana- 
lyzed with a FACScan  |  flow cytometer. 
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~" chain was  selectively  lost from the TCR-CD3  complex 
without being replaced  by FcR3' in the spleen  of TBM. 
Progressive Increases of Non-T, Non-B Cells in the Spleen of 
TBM.  To liberate T cells from in vivo influences of tumor, 
splenocytes  from TBM were cultured in vitro for 48 h. Ir- 
respective ofT cell stimulation with PMA and Ca ionophore, 
the ~"  chain remained undetectable in TBM (data not shown). 
Cell surface staining of TBM splenocytes revealed increases 
in non-T, non-B cell populations (T-B-) alone with tumor 
progression (Fig.  1 B). The accumulation of T-B-  cells oc- 
curred only in the spleen but much less in lymph nodes and 
i-IEL and in parallel with splenomegaly (Fig. 2 B).  In con- 
trast with the complete loss of ~" in splenic  T  cells,  ~" was 
detected within the TCR. complex in both lymph nodes and 
i-IEL from the same mouse (Fig. 2 A). Therefore, the altera- 
tion of the TCR structure is induced in localized tissues and 
is not systemic,  and the accumulation of T-B-  cells corre- 
lates  with the loss  of ~'. 
Splenocytes  from TBM Cause the Structural  Alterations of TCR 
in Normal T Cells.  To examine the capability of splenocytes 
from TBM or tumor cells to induce the loss of ~', we used 
in vitro culture by mixing these cells or culture supernatants 
with freshly isolated normal splenic T cells. Fig. 3 A clearly 
demonstrates that the coculture of T cells with TBM spleno- 
cytes but not with tumor cells or supernatants resulted in 
the loss of ~'. It should be stressed  that in addition to the 
disappearance of ~', the mobility of the CD33'Se  chains were 
increased.  Again, the expression  level of the cell surface of 
the TCR complex was not changed during the period (data 
not shown). Surprisingly, these structural changes were in- 
duced by just performing surface biotinylation immediately 
after mixing normal T  cells and TBM splenocytes.  When 
normal T cells were separated from TBM splenoeytes by pored 
membrane to prevent  direct contact, no structural changes 
were observed  after culture for 12 h (Fig. 3 B) or even 48 h 
(data not shown). These results suggest that direct cell con- 
tact with TBM splenocytes induced the TCR alterations in 
normal T  cells. 
Direct Interaction with Macrophages  from  TBM Induces the 
Structural Alterations of the TCR Complex.  The T-B-  cells 
accumulated in the spleen of  TBM were characterized by cell 
surface staining. Staining profiles revealed that CD3-B220- 
cells  were  the major population  in  the  TBM  spleen  and 
Mac-1 +, MHC class II  l~  HSA + (Fig. 4), and Gr-1-  (data 
not shown). These phenotypes are consistent with those of 
tumor-induced macrophages (15). When macrophages were 
isolated from TBM and cocultured with normal T cells, they 
induced the structural changes of the TCR complex, the dis- 
appearance  of ~" and mobility shifts of the CD33'~ chains 
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Figure 2.  Structure  of the TCR-CD3 com- 
plex and flow  cytometric  analysis  of cells from 
spleen, lymph  nodes, and i-IEL  in 9-wk TBM. 
(A) Splenic  T cells (1.5 x 107), whole  lympho- 
cytes (4 ￿  107, ,v40% were T cells), and i-IEL 
(1  ￿  107) were surface  biotinylated,  and the ly- 
sates were  precipitated  with anti-CD3e  mAb and 
analyzed  as in Fig. 1. FcR3' chain (A) was seen 
in i-IEL (14). The position of each CD3 chain 
and molecular  size markers (in kilodaltons)  are 
indicated. (B) Each  population  in A was stained 
with FITC-labeled  anti-CD3e  and PE-conjugated 
anti-CD45R/B220 mAbs and analyzed  with a 
FACScan  |  flow cytometer. A 
Normal  TBM 
Mac-1 
HSA 
MHC 
class II 
Fluorescence Intensily (log) 
Mac-1 
HSA 
NormalpM~  Zym + LPS pM  0 
Figure  3.  Structural alterations of the TCR complex in normal splenic 
T cells by coculture with TBM splenocytes. (A) Normal splenic T  cells 
(1.5  ￿  107) were mixed with medium alone (lane I), whole splenocytes 
from TBM (7.5  ￿  106, lane 2),  culture supernatant  of TBM splenocytes 
(lane 3), colon 26 tumor cells (7.5  x  106, lane 4), and culture superna- 
tant of the tumor cells (lane 5), respectively. After a 12-h incubation,  cells 
were surface-biotinylated  and the lysates were immunoprecipitated  with 
anti-CD3e and -~" mAbs, and they were analyzed on 13% reducing  SDS- 
PAGE. sup,  supernatant.  (B) Whole spleen cells from normal mice (1.5 
x  10  ~, lane I) or from TBM (1.5  x  107, lane 3) were co-cultured with 
normal  splenic T cells (3  x  l0  T) for 12 h. For lane 2, whole spleencells 
from TBM (1.5  x  107) were mixed with normal splenic T  cells (3  x 
107), and the mixture was immediately harvested. In lane 4, TBM spleno- 
cytes (1.5  ￿  107) and normal  splenic T  cells (3  x  107) were cocuhured 
for 12 h under separated condition by pored membrane.  Cells were ana- 
lyzed as in A. The positions of CD3"ySe and ~"  chains, as well as molecular 
size markers  (in kilodaltons),  are indicated. 
in a dose-dependent fashion; however, splenic macrophages, 
as well as peritoneal macrophages from normal mice, failed 
to induce these changes in T  cells  (Fig.  5). 
Normal Activated Macrophages Exhibit  Similar Capacity to 
Induce the Alteration of the TCR Complex.  We next analyzed 
whether normal macrophages in certain activated stages ex- 
hibit similar capability to induce the structural changes of 
the TCR complex, or if only macrophages from TBM are 
special. Peritoneal macrophages were activated with thioglyco- 
late, zymosan A, and LPS, separately or together. Only mac- 
rophages  activated with  zymosan A  +  LPS  induced the 
disappearance of ~" (Fig.  5 C), whereas other activated mac- 
rophages failed to induce such alterations. FACS  |  analysis re- 
vealed that zymosan A  +  LPS-treated peritoneal macrophages 
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Figure  4.  Flow cytometric analysis of T-B-  cells in  the spleen of 
normal mice and TBM (A), and peritoneal macrophages from normal and 
zymosan A  +  LPS-treated  mice (B). T-B-  cells and peritoneal  macro- 
phages were prepared as described in Materials and Methods.  Cells were 
stained with mAbs against  Mac-l, MHC class II, and HSA (thick  lines) 
or with control Ab (thin line), followed by FlTC-labeled  anti-rat Ig mAb, 
and  analyzed with a FACScan  |  flow cytometer. 
showed similar phenotype of Mac-1 + ,  HSA § ,  and MHC 
classlP  w as macrophages observed in TBM (Fig.  4).  These 
results clearly demonstrate that not only macrophages from 
TBM, but also normal macrophages in certain activated stages, 
can induce the structural alterations of the TCR complex 
in normal T  cells. 
Discussion 
Alterations of the expression of the TCR complex and the 
associated kinases were first reported by Mizoguchi et al. (4). 
In the present study, we partly confirmed this phenomenon 
and extended the analysis to understand the mechanism. We 
observed the disappearance of the CD3~" chain along with 
tumor progression in a TBM model. Our main finding was 
that macrophages accumulated in the spleen of TBM induced 
the disappearance of ~" in all splenic T cells. This was clearly 
demonstrated by devising an in vitro culture system in which 
fleshly prepared normal T cells lost the ~'chain by direct contact 
with macrophages from TBM. This finding explains the ob- 
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T cells from the spleen but not from lymph nodes or i-IEL, 
because the extensive accumulation of macrophages was ob- 
served only in the spleen but not in the latter tissues. Recent 
analyses on human cancer patients that tumorqnfiltrating T 
cells expressed less amount of ~" than peripheral blood T cells 
in the same individual (5, 6) could be attributable to macro- 
phages  (16) that interact with T  cells in tumor lesions  and 
may cause the alterations of the TCK structure. The lesser 
effect in peripheral blood T cells may be caused by the small 
number of such macrophages in peripheral blood. Since splenic 
T cells are separated  from the subcutaneous tumors, tumor 
cells have a minimal influence on T  cells but rather are in- 
directly involved by inducing functional changes in macro- 
phages. 
Several possible mechanisms have been proposed to explain 
the  impaired  immune  responses  in  tumor-bearing  hosts. 
Among them, the contribution of suppressor  macrophages 
has been extensively studied (3,  14,  17). Macrophages play 
a major role in the host-defense mechanism through phago- 
cytosis  and production of inflammatory cytokines, as well 
as in antigen presentation to T cells. Tumor growth induces 
functional changes in macrophages from immunocompetent 
to immunosuppressive. One of the notable phenotypic changes 
is the downregulation of the surface expression of MHC class 
II molecules, as we observed in the accumulated macrophages 
in TBM. These macrophages have been demonstrated to sup- 
press T cell functions by producing inhibitory mediators such 
as prostaglandin E2  (3)  and lipocortin (17). On  the other 
hand, it has been reported that surface molecules on T cells, 
such as membrane-bound TNF-c~,  activate macrophages to 
induce effector functions (18). Taken together with our re- 
sult that the cell contact between macrophages and T  cells 
is required to induce the alteration of the TCK complex, it 
is likely that macrophages activated to certain stages in TBM 
interact with T cells and induce structural alterations of the 
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Figure  5.  Structural  alterations  of  the TCK complex 
in normal  splenic  T cells  by coculture  with macrophages 
in the spleen of TBM or zymosan  A + LPS-treated 
peritoneal macrophages. (.,t) Medium alone (lane I), 
splenocytes  from  normal  mice (1  x 107, lane  2), splenic 
macrophages from normal mice (1  x  107, lane 3), 
splenocytes  from TBM (1  x  107, lane 4), and splenic 
macrophages from  TBM (1  x  107, lane  5) were mixed 
with normal splenic T cells (2 x  107). After a 30-min 
culture, cells were surface  biotinylated  and the lysates 
were precipitated  with anti-CD3e  and -~"  mAbs, and they 
were analyzed  on 13% reducing  SDS-PAGE. (B) Peri- 
toneal macrophages (pM$) from normal mice 2.5  x 
106, lane  I) and graded  cell numbers of splenocytes  from 
TBM (7.5  x  10  6, lane  2; 2.5  x 106, lane  3; 7.5 x 105, 
lane 4) were mixed  with normal splenic  T cells (1.5 x 
107). After a 1-h coculture,  cells were  analyzed  as in A. 
(C) Medium  alone  (lane I), splenocytes  from  3-wk  TBM 
(1.5  x  107, lane  2), splenocytes  from 6-wk TBM (1.5 
x 107, lane  3), peritoneal  macrophages  from zymosan 
A + LPS-treated  mice (1.5  x  107, lane 4), and peri- 
toneal macrophages  from thioglycolate-treated  mice  (1.5 
x 107, lane  5) were mixed  with normal  splenic T cells 
(1.5  x  107). After a 1-h coculture,  cells were analyzed 
as in A. The positions  of CD3y~e and ~'chains,  as well 
as molecular size markers (kilodaltons), are indicated. 
TCR complex by direct contact or by secreting short-lived 
mediators upon interactions. 
More importantly, we found that the alterations of the 
TCR complex could be induced not only by macrophages 
from TBM but also by activated macrophages from normal 
mice. The findings that macrophages activated with zymosan 
A  +  LPS but not with thioglycolate induced the changes 
of the TCR complex by mixing with normal T  cells imply 
that macrophages in certain activation stages have the capa- 
bility to induce the structural alterations of the TCK com- 
plex by direct cell contact. Such activated macrophages may 
be readily induced in inflammatory  lesions or upon bacterial 
infections, as well as in tumor-bearing conditions. Therefore, 
macrophages might regulate the structure of the TCK com- 
plex and related signaling functions in normal immune re- 
sponses. 
The intracellular events induced in T  cells by suppressive 
macrophages remain unknown. Although Mizoguchi et al. 
reported that ~" was replaced by the FcR3~ chain and the ex- 
pression  of CD3  3' was reduced in TBM, our results could 
not confirm these changes but rather demonstrated different 
alterations.  In our model, ~'disappeared but was not replaced 
by Fcl~% In our in vitro analysis, TBM macrophages induced 
the loss of ~" in normal T cells just by mixing the two popu- 
lations, without incubation.  Our  in vitro analysis  clearly 
demonstrated the mobility shifts of CD3~/6e, suggesting struc- 
tural or conformational changes of each CD3 chain. A similar 
observation has been reported in invariant chain (Ii)-deficient 
mice, that the MHC class II oe3 dimers possessing  unusual 
conformations in the absence of Ii exhibit a mobility shift 
in SDS-PAGE (19). Since the interaction of T cells with small 
number of macrophages induced only the disappearance  of 
~" and the mobility shift of other CD3 chains required more 
macrophages, the loss of ~" seems to be more sensitive than 
structural changes of other CD3 chains to the putative signals 
from macrophages. Alternatively, there may exist two different 
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tural changes of other CD3 chains. Analysis of the structural 
basis of the CD3 chains' mobility shift could be a clue for 
analyzing the mechanism. 
The ~" chain has been shown to regulate the intracellular 
assembly and cell surface expression of the TCR-CD3 com- 
plex. Previous studies in vivo and in vitro demonstrated that 
the TCR-CD3 components failed to express on the cell sur- 
face in the absence of ~" (10,  11). Therefore, the mechanism 
for maintaining the normal level of cell surface TCR expres- 
sion in the absence of ~" in TBM is not clear at the present 
time. Further analysis of the mechanism of the TCR com- 
plex alterations induced by activated macrophages may pro- 
vide greater insight into the assembly and transport of the 
TCR-CD3  complex, as well as effective therapies for im- 
munosuppression. 
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